# JW Therapeutics

> JW Therapeutics (HKEx: 2126) is an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products. Since its founding in 2016, JW Therapeutics has built an integrated platform for product development in cell immunotherapy, as well as a product pipeline covering hematologic malignancies, solid tumors, and autoimmune diseases. JW Therapeutics is committed to bringing breakthrough and quality cell immunotherapy products and the hope of a cure to patients in China and beyond, and to leading the healthy and standardized development of China's cell immunotherapy industry.

Official website: https://www.jwtherapeutics.com

## Overview

JW Therapeutics (HKEx: 2126) is an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products. Since its founding in 2016, JW Therapeutics has built an integrated platform for product development in cell immunotherapy, as well as a product pipeline covering hematologic malignancies, solid tumors, and autoimmune diseases.

JW Therapeutics is committed to bringing breakthrough and quality cell immunotherapy products and the hope of a cure to patients in China and beyond, and to leading the healthy and standardized development of China's cell immunotherapy industry.

## Vision and Mission

**VISION:** Become an Innovation Leader in Cell Immunotherapy

**MISSION:**
- Bring Hope to Patients in China
- Work Together and Realize the Potential for JW Therapeutics and Its Employees

## Lead Product

**Carteyva®** (relmacabtagene autoleucel injection; codename JWCAR029; also known as relma-cel) is JW Therapeutics' lead CAR-T cell immunotherapy product.

## Corporate Milestones

- **2016 Feb** — JW Therapeutics founded in Shanghai
- **2016 Jul** — GMP cell therapy manufacturing infrastructure first put into use
- **2017 Jul** — Introduced world-class CAR-T technology platform and completed technology development
- **2018 May** — Completed series A financing totaling over USD 100 million
- **2018 Sep** — JW Therapeutics (Suzhou) Co., Ltd. founded
- **2018 Nov** — Started world-leading commercial scale cell therapy manufacturing project
- **2018 Dec** — JW Therapeutics R&D center opened
- **2019 Feb** — Recognized as a "Foreign-invested R&D center" by Shanghai Municipal People's Government
- **2019 Oct** — Outstanding Enterprise in the Growth Group of the China Innovation and Entrepreneurship Competition of the Ministry of Science and Technology
- **2019 Dec** — Completed cell therapy commercial-scale manufacturing infrastructure in Suzhou
- **2019 Dec** — GMP quality management lab put into use
- **2020 Jan** — Zhangjiang Science City Outstanding Enterprise Innovation and Development Award
- **2020 May** — Completed USD 100 million series B financing
- **2020 Jun** — Acquired Syracuse Biopharma
- **2020 Jun** — Suzhou site obtained drug manufacturing license
- **2020 Nov** — Listed on the main board of the Hong Kong Exchanges and Clearing Limited, stock code 2126.HK
- **2021 Sep** — Became the market authorization holder (MAH) for cell therapy product, and entered commercial stage
- **2022 Feb** — Shanghai CAR-T Cell Immunotherapy Technology Innovation Center
- **2022 Dec** — High-tech enterprises
- **2023 Mar** — Specialized, Refined, Distinctive and Innovative SMEs in Shanghai
- **2023 Dec** — Pudong New Area Research and Development Institutions
- **2024 Dec** — "CNR" Corporate Social Responsibility ESG Era Pioneer Award
- **2025 Apr** — JW Therapeutics Announces sLVV License Agreement with Juno Therapeutics
- **2025 Oct** — JW Therapeutics and Regeneron Expand Strategic Collaboration Agreement

## Product Milestones

- **2017 Dec** — Relma-cel was infused for treatment in the first patient
- **2018 Jun** — Relma-cel obtained first approval for clinical trial of CAR-T product targeting CD19 under IND pathway in China
- **2019 Apr** — Successfully introduced BCMA-targeted cell therapy drug candidate (codename: JWCAR129)
- **2019 Jun** — Relma-cel was included in the National Significant New Drug Development Program
- **2019 Dec** — Relma-cel was included in the National Significant New Drug Development Program
- **2020 Jun** — Successfully submitted relma-cel's NDA for its first indication LBCL
- **2020 Sep** — Relma-cel was granted priority review for its new drug application, and Breakthrough Therapy Designation
- **2021 Sep** — Relma-cel was approved and launched in China
- **2021 Sep** — Received the IND approval for clinical trial of JWCAR129
- **2022 Mar** — Received the IND clearance for clinical trial of Carteyva® on 2L LBCL
- **2022 Apr** — Received the IND clearance for clinical trial of Carteyva® on pALL
- **2022 Apr** — CARTEYVA® has been granted Breakthrough Therapy Designation in China for the indication of mantle cell lymphoma (MCL)
- **2022 Jun** — Initiated the clinical study in solid tumors, and infused the first HCC patient for treatment
- **2022 Sep** — Relma-cel was approved for FL indication in China
- **2023 Jan** — Carteyva® was included in the "Shanghai Recommended Catalogue of Innovative Products"
- **2023 Apr** — The clinical trial application for the indication of CARTEYVA® 2L LBCL (adult relapsed or refractory large B-cell lymphoma after first-line treatment failure and unsuitable for high-dose chemotherapy and autologous stem cell transplantation) has been approved
- **2023 Apr** — The clinical trial application for CARTEYVA® in systemic lupus erythematosus (SLE) has been approved
- **2023 May** — Carteyva® was included in the "Shanghai Biopharmaceutical Product Catalogue of 'New and Excellent Drug and Equipment'"
- **2023 Jun** — Carteyva® was included in the "Shanghai Pudong New Area Recommended Catalogue of Innovative Drug and Equipment"
- **2024 Mar** — Carteyva® received Shanghai High-tech Achievements Transformation Certification
- **2024 Jul** — Carteyva® was included in the "Suzhou Famous and Innovative Products in Biopharmaceutical and Health Industry"
- **2024 Aug** — CARTEYVA® has been approved in China for the indication of mantle cell lymphoma (MCL)
- **2025 Jan** — The indication of CARTEYVA® 2L LBCL (relapsed or refractory large B-cell lymphoma in adults who are not suitable for high-dose chemotherapy and autologous stem cell transplantation after first-line treatment failure) has been granted Breakthrough Therapy Designation in China
- **2025 May** — NMPA acceptance of the supplemental biological license application for CARTEYVA® as second-line treatment in relapsed or refractory large B-cell lymphoma ineligible for autologous stem cell transplantation
- **2025 Jun** — Approval of Carteyva® (Relmacabtagene Autoleucel Injection) for marketing in Macao
- **2025 Oct** — National Medical Products Administration has officially accepted the post-marketing supplemental application for Carteyva®, which uses an in-house produced lentiviral vector
- **2025 Dec** — JW Therapeutics' Carteyva® successfully included in the first edition of the National Healthcare Security Administration's Commercial Health Insurance Innovative Drug Directory

## Contact

**Headquarters**
Building B, 5/F, Wison Center
666 Haike Road, Pudong New Area
Shanghai, China
Postal Code: 201210
Tel: +86 21 50783699

**Media Relations and Business Development**
- Media Relations: Communications@jwtherapeutics.com
- Business Development: BD@jwtherapeutics.com

**Medical Information and Adverse Event Reporting**
- Medical Information: Medical.Information@jwtherapeutics.com
- Pharmacovigilance (AE): PV@jwtherapeutics.com

**Whistle-blowing Reporting Channel**
- Compliance: compliance@jwtherapeutics.com
- Internal Audit: IA@jwtherapeutics.com

**Customer Service Hotline**
400 820 0033 (09:00–18:00 on work days)

## Quick Access

- [Homepage (Chinese, default)](https://www.jwtherapeutics.com/cn/): 药明巨诺官方网站 — corporate website and company overview
- [Homepage (English)](https://www.jwtherapeutics.com/en/): Corporate website and company overview
- [Careers Development](https://www.jwtherapeutics.com/en/careers-development/): Job opportunities and talent development
- [Investor Relations](https://www.jwtherapeutics.com/en/investor-relations/): Financial reports, announcements, and stock information (HKEx: 2126)
- [Sitemap](https://www.jwtherapeutics.com/sitemap.xml): Full site index

## Optional

- [Robots.txt](https://www.jwtherapeutics.com/robots.txt): Crawler and indexing rules for this website